Boston Scientific Corporation (BSX), Edwards Lifesciences Corp (EW): An Easy Way to Profit From Obamacare-Driven Health-Care Growth

Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you. If you’d like to add some health-care equipment stocks to your portfolio, but don’t have the time or expertise to hand-pick a few, the SPDR S&P Health-Care Equipment ETF could save you a lot of trouble. Instead of trying to figure out which companies will perform best, you can use this ETF to invest in lots of them simultaneously.

The basics
ETFs often sport lower expense ratios than their mutual fund cousins. The SPDR ETF’s expense ratio — its annual fee — is a low 0.35%. The fund is fairly small, too, so if you’re thinking of buying, beware of possibly large spreads between its bid and ask prices. Consider using a limit order if you want to buy in.

This ETF is too new to have much of a track record to assess. For what it’s worth, it underperformed the world market last year, and is ahead of it this year. As with most investments, of course, we can’t expect outstanding performances in every quarter or year. Investors with conviction need to wait for their holdings to deliver.

Why health care?
For starters, our planet’s growing, and our aging population will keep demand rising for health-care products and services. On top of that, Obamacare is likely to usher more Americans into health coverage, delivering more consumers to companies treating them.

More than a handful of health-care equipment companies had strong performances over the past year. Stent and defibrillator specialist Boston Scientific Corporation (NYSE:BSX) surged 114%, in part due to its gaining FDA approval for a new catheter, and also for its small, but growing, electrophysiology business. The company has topped expectations recently, and has been improving some of its performance numbers, such as profit margins.

The stock yields 1.6%, which reflects a recent 10% dividend boost as well as a big hike in the company’s stock-buyback program. That signals confidence, but the shares may not exactly be bargains, with a P/E ratio near 20, well above its 11.7 five-year average.